Total Payments
$710,421
2024 Payments
$7,418
Companies
61
Transactions
1,630
Medicare Patients
2,500
Medicare Billing
$186,153
Payment Breakdown by Category
Other$508,817 (71.6%)
Travel$114,663 (16.1%)
Consulting$61,028 (8.6%)
Food & Beverage$25,494 (3.6%)
Education$419.32 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $502,404 | 240 | 70.7% |
| Travel and Lodging | $114,663 | 177 | 16.1% |
| Consulting Fee | $61,028 | 56 | 8.6% |
| Food and Beverage | $25,494 | 1,141 | 3.6% |
| Honoraria | $5,848 | 3 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.1% |
| Education | $419.32 | 12 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $144,578 | 277 | $0 (2024) |
| Celgene Corporation | $131,583 | 128 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $103,508 | 139 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $69,967 | 72 | $0 (2024) |
| Clovis Oncology, Inc. | $39,501 | 56 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $33,619 | 122 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $28,814 | 33 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $23,843 | 38 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $21,996 | 28 | $0 (2019) |
| Taiho Oncology, Inc. | $15,099 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,418 | 63 | Lilly USA, LLC ($6,272) |
| 2023 | $32,413 | 37 | E.R. Squibb & Sons, L.L.C. ($22,918) |
| 2022 | $66,082 | 57 | Lilly USA, LLC ($29,706) |
| 2021 | $76,209 | 91 | Lilly USA, LLC ($38,885) |
| 2020 | $61,594 | 183 | Celgene Corporation ($26,589) |
| 2019 | $182,521 | 452 | Celgene Corporation ($32,538) |
| 2018 | $165,539 | 421 | Takeda Pharmaceuticals U.S.A., Inc. ($35,020) |
| 2017 | $118,644 | 326 | Celgene Corporation ($36,075) |
All Payment Transactions
1,630 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $16.63 | General |
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $17.15 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $9.90 | General |
| Category: Hematology | ||||||
| 11/08/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $10.64 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Oncology | ||||||
| 10/21/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $15.89 | General |
| 10/03/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Oncology | ||||||
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Oncology | ||||||
| 08/19/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Oncology | ||||||
| 08/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: Oncology | ||||||
| 07/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.63 | General |
| Category: Hematology | ||||||
| 07/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.57 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 494 | 1,226 | $143,399 | $47,191 |
| 2022 | 1 | 11 | 11 | $2,024 | $783.86 |
| 2021 | 12 | 658 | 2,929 | $201,415 | $42,022 |
| 2020 | 21 | 1,337 | 7,012 | $473,083 | $96,157 |
Total Patients
2,500
Total Services
11,178
Medicare Billing
$186,153
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 162 | 410 | $77,087 | $26,129 | 33.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 119 | 281 | $37,925 | $11,307 | 29.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 74 | 74 | $20,322 | $5,883 | 28.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 139 | 461 | $8,065 | $3,872 | 48.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $2,024 | $783.86 | 38.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 225 | 540 | $24,698 | $12,586 | 51.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 17 | 92 | $46,000 | $10,098 | 22.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 98 | 269 | $40,350 | $9,660 | 23.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 70 | 202 | $20,200 | $2,113 | 10.5% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 13 | 157 | $15,700 | $1,948 | 12.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 73 | 226 | $22,600 | $1,741 | 7.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 18 | $4,140 | $1,197 | 28.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 80 | 237 | $17,775 | $708.00 | 4.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 13 | 13 | $1,809 | $663.05 | 36.7% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Facility | 2021 | 17 | 17 | $1,568 | $626.58 | 40.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 14 | 45 | $4,500 | $467.04 | 10.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 12 | 1,100 | $1,100 | $127.01 | 11.5% |
| 83735 | Magnesium level | Office | 2021 | 11 | 13 | $975.00 | $87.10 | 8.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 322 | 1,055 | $47,063 | $19,413 | 41.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 41 | 178 | $83,228 | $19,322 | 23.2% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 134 | 484 | $64,314 | $15,455 | 24.0% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2020 | 12 | 140 | $33,269 | $8,560 | 25.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 75 | 114 | $23,842 | $6,340 | 26.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 130 | 443 | $44,370 | $4,622 | 10.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 149 | 542 | $54,200 | $4,153 | 7.7% |
About Dr. Joseph Readling, MD
Dr. Joseph Readling, MD is a Hematology & Oncology healthcare provider based in Binghamton, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275522831.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Readling, MD has received a total of $710,421 in payments from pharmaceutical and medical device companies, with $7,418 received in 2024. These payments were reported across 1,630 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($502,404).
As a Medicare-enrolled provider, Readling has provided services to 2,500 Medicare beneficiaries, totaling 11,178 services with total Medicare billing of $186,153. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Binghamton, NY
- Active Since 10/17/2005
- Last Updated 02/22/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275522831
Products in Payments
- NINLARO (Drug) $97,340
- VERZENIO (Drug) $77,649
- Revlimid (Drug) $52,268
- REBLOZYL (Biological) $39,692
- Rubraca (Drug) $39,501
- OPDIVO (Biological) $36,190
- Abraxane (Drug) $29,214
- Pomalyst (Drug) $25,698
- Imbruvica (Drug) $23,843
- KISQALI (Drug) $16,547
- EMPLICITI (Biological) $14,837
- Lonsurf (Drug) $13,789
- SARCLISA (Biological) $13,302
- Copiktra (Drug) $12,285
- RETEVMO (Drug) $12,166
- JADENU (Drug) $10,214
- XTANDI (Drug) $9,880
- Udenyca (Biological) $9,022
- ZEJULA (Drug) $9,001
- GAZYVA (Biological) $6,847
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.